Holen Sie sich die Stockscreener-App
3.92
5.95%
0.22
Schlusskurs vom Vortag:
$3.70
Offen:
$3.78
24-Stunden-Volumen:
2.64M
Relative Volume:
1.87
Marktkapitalisierung:
$302.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-78.15M
KGV:
-4.5725
EPS:
-0.8573
Netto-Cashflow:
$-68.89M
1W Leistung:
+9.80%
1M Leistung:
+9.50%
6M Leistung:
+149.68%
1J Leistung:
+41.01%
1-Tages-Spanne:
$3.75
$3.96
1-Wochen-Bereich:
$3.4101
$3.96
52-Wochen-Spanne:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Firmenname
Eledon Pharmaceuticals Inc
Sektor
Branche
Telefon
949-238-8090
Adresse
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.92 | 302.58M | 0 | -78.15M | -68.89M | -0.8573 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Guggenheim | Buy |
| 2022-05-13 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Aktie (ELDN) Neueste Nachrichten
Eledon Pharma To Present At The American Transplant Congress - RTTNews
Eledon Pharmaceuticals Inc (ELDN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Institutional Confidence - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ELDN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
symbol__ Stock Quote Price and Forecast - CNN
Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart - Insider Monkey
10 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Eledon trial shows all 12 diabetes patients achieve insulin independence By Investing.com - Investing.com Australia
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tego - GuruFocus
Midday Stock Roundup: Eledon Up 4% on T1D Trial Results - Orange County Business Journal
Eledon Pharmaceuticals stock surges on diabetes trial results By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals stock surges on diabetes trial results - Investing.com
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tegoprubart in T1D Trials - GuruFocus
Eledon trial shows all 12 diabetes patients achieve insulin independence - Investing.com
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine - The Manila Times
12 longtime type 1 diabetes patients stop insulin after islet transplant - Stock Titan
Eledon Pharmaceuticals Inc (ELDN) Stock Price, Quote, News & History - Benzinga
Eledon presents updated trial data on tegoprubart for type 1 diabetes at ADA 2026. - Pluang
Eledon trial results to be presented at diabetes conference By Investing.com - Investing.com South Africa
Eledon trial results to be presented at diabetes conference - Investing.com
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions - The Manila Times
Type 1 diabetes islet transplant brings updated tegoprubart data to ADA - Stock Titan
Eledon Pharmaceuticals, Inc. - MLQ.ai
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Breakthrough in Diabetes Treatment with ELDN's New Drug Submissi - GuruFocus
EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND SubmissionEledon Pha - Benzinga
Stem cell therapy targeting a potential type 1 diabetes cure nears trials - Stock Titan
ELDN Technical Analysis & Stock Price Forecast - Intellectia AI
Eledon to present kidney transplant trial data at conference - Investing.com UK
Eledon to present kidney transplant trial data at conference By Investing.com - Investing.com Australia
Eledon to present new Phase 2 data on tegoprubart for kidney transplant rejection at June congress - Pluang
New kidney transplant rejection data from tegoprubart at ATC - Stock Titan
Eledon Pharmaceuticals to Present New Long-Term Data from - GlobeNewswire
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TradingKey - TradingKey
BVF Group Discloses Convertible Stakes in Eledon (ELDN) — 9.99% Blockers - Stock Titan
Eledon Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $8.2, Implies 111% Upside - TradingView
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Raises Target Price to $6 - Moomoo
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
How Should Investors Value Eledon Pharmaceuticals (ELDN) After Q - GuruFocus
Eledon (ELDN) Advances in Tegoprubart Development with Key Miles - GuruFocus
Eledon Pharmaceuticals (ELDN) Reports Q1 Loss, Cash Reserves Dec - GuruFocus
Eledon Pharma Expects Cash, Cash Equivalents and Short-Term Investments to Fund Ops Into 2Q 2027 >ELDN - Moomoo
Finanzdaten der Eledon Pharmaceuticals Inc-Aktie (ELDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):